Vis enkel innførsel

dc.contributor.authorNieminen, Markku S.en_US
dc.contributor.authorDickstein, Kennethen_US
dc.contributor.authorFonseca, Cândidaen_US
dc.contributor.authorSerrano, Jose Magañaen_US
dc.contributor.authorParissis, Johnen_US
dc.contributor.authorFedele, Francescoen_US
dc.contributor.authorWikström, Gerharden_US
dc.contributor.authorAgostoni, Piergiuseppeen_US
dc.contributor.authorAtar, Shaulen_US
dc.contributor.authorBaholli, Loanten_US
dc.contributor.authorBrito, Dulceen_US
dc.contributor.authorColet, Josep Cominen_US
dc.contributor.authorÉdes, István Ferencen_US
dc.contributor.authorGómez Mesa, Juan E.en_US
dc.contributor.authorGorjup, Vojkaen_US
dc.contributor.authorGarza, Eduardo Herreraen_US
dc.contributor.authorGonzález Juanatey, José R.en_US
dc.contributor.authorKaranovic, Nenaden_US
dc.contributor.authorKaravidas, Apostolosen_US
dc.contributor.authorKatsytadze, Igoren_US
dc.contributor.authorKivikko, Mattien_US
dc.contributor.authorMatskeplishvili, Simonen_US
dc.contributor.authorMerkely, Bélaen_US
dc.contributor.authorMorandi, Fabrizioen_US
dc.contributor.authorNovoa, Angelen_US
dc.contributor.authorOliva, Fabrizioen_US
dc.contributor.authorOstadal, Petren_US
dc.contributor.authorPereira-Barretto, Antonioen_US
dc.contributor.authorPollesello, Pieroen_US
dc.contributor.authorRudiger, Alainen_US
dc.contributor.authorSchwinger, Robert HGen_US
dc.contributor.authorWieser, Manfreden_US
dc.contributor.authorYavelov, Igoren_US
dc.contributor.authorZymlinski, Roberten_US
dc.PublishedInternational Journal of Cardiology 2015, 191:256-264eng
dc.description.abstractEnd of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.en_US
dc.rightsAttribution CC BY-NC-NDeng
dc.titleThe patient perspective: Quality of life in advanced heart failure with frequent hospitalisationsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2015 the authors

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC-ND